Jefferson University Hospitals

Provider Profile

Daniel P. Silver, MD, PhD

Daniel P. Silver, MD, PhD

Jefferson University Physician

Academic Title: Associate Professor
Director, Basic Science and Research in Medical Oncology
Leader, Breast Program, Sidney Kimmel Cancer Center

Specialties
Medical Oncology
Medical Oncology - Breast Cancer

Make An Appointment

Click to call 1-800-JEFF-NOW (800-533-3669) or

Office Locations

Philadelphia
925 Chestnut Street
Suite 420A
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 955-9641
Philadelphia
1100 Walnut Street
3rd Floor
Philadelphia PA 19107
Phone: (215) 955-8874
Fax: (215) 503-2230

Medical Services

Board Certifications

  • Medical Oncology

Hospital Affiliation / Admitting Privileges

  • Thomas Jefferson University Hospital
  • Methodist Hospital Division of Thomas Jefferson University Hospital

Awards and Honors

Fellow of the College of Physicians of Philadelphia 2016

Education

  • University of California/San Francisco, Medical School

Internship

  • University of California, San Francisco

Residency

  • University of California, San Francisco

Fellowship

  • Dana Farber Cancer Institute

Jefferson physicians accept most health insurance plans, including those listed below. However, plan acceptance may vary by practice and may be subject to change. If you have questions about whether a specific physician accepts your insurance, please contact your insurance company.

Insurances Accepted

  • Aetna
  • Aetna PA Employee Benefit Trust Fund (PEBTF)
  • Amer Assoc Retired Persons (AARP)
  • AmeriHealth
  • Amerihealth Caritas
  • AmeriHealth Comprehensive
  • AmeriHealth HMO
  • AmeriHealth Major Medical
  • AmeriHealth Personal Choice
  • BC BS Special Care
  • Blue Choice
  • Blue Cross/Blue Shield
  • Blue Cross/Blue Shield of Delaware
  • Cigna Healthspring
  • Cigna PPO, POS
  • Consumer Health Network PPO
  • CorVel
  • Coventry/Health America
  • Delaware Blue Cross/Blue Shield
  • Devon
  • Empire BC/BS
  • Employers Health Network PPO
  • Evolutions (Guardian Resources)
  • Federal BCBS
  • First Health Network
  • Galaxy
  • Geisinger Health Plan
  • Health America PPO
  • Health Management Network PPO
  • Horizon Blue Cross/Blue Shield
  • Horizon HMO
  • HumanaChoicePPO,Medicare,GoldPlusHMO
  • Inter-County Health Plan
  • Intergroup Preferred
  • Jeff Plus
  • Keystone 65 HMO
  • Keystone First VIP Choice
  • Keystone First/Connect
  • Keystone Health Plan East
  • Medallion of New Jersey
  • Medicaid of PA
  • Medicare
  • Mercy LIFE
  • MultiPlan Inc.
  • NJ Blue Shield
  • NJ Plus
  • Oxford of PA
  • Personal Choice (GPPPN)
  • Personal Choice 65
  • PlanCare America
  • Postal Workers/Mailhandlers
  • PPO Next
  • Preferred Care PPO
  • Premier Blue
  • Prime Health Services, Inc.
  • Private Healthcare Systems (PHCS)
  • Qualcare
  • Tricare
  • United Healthcare
  • UPMC HMO,PPO ReadingHspEmpONLY
  • UPMC Medicare HMO
  • US Family Health Plan

Recent Publications

Overexpression of BLM promotes DNA damage and increased sensitivity to platinum salts in triple-negative breast and serous ovarian cancers

Zoledronic acid alters hematopoiesis and generates breast tumor-suppressive bone marrow cells

MECP2 is a frequently amplified oncogene with a novel epigenetic mechanism that mimics the role of activated RAS in malignancy

BRCA1 pathway function in basal-like breast cancer cells

Mechanisms of BRCA1 tumor suppression

Mutational processes molding the genomes of 21 breast cancers

Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents

Chek2 DNA damage response pathway and inherited breast cancer risk

Poly ADP-ribose polymerase inhibitors: Science and current clinical development

Prevalence and predictors of loss of wild type BRCA1 in estrogen receptor positive and negative BRCA1-associated breast cancers

Poly(ADP-ribose) polymerase inhibition: "Targeted" therapy for triple-negative breast cancer

Efficacy of neoadjuvant cisplatin in triple-negative breast cancer

Complex landscapes of somatic rearrangement in human breast cancer genomes

Estrogen receptor-negative breast cancer: New insights into subclassification and targeting

Cyclin A Is Redundant in Fibroblasts but Essential in Hematopoietic and Embryonic Stem Cells

Synthetic lethality - A new direction in cancer-drug development

Cancer: Crossing over to drug resistance

Further Evidence for BRCA1 Communication with the Inactive X Chromosome

Abnormalities of the inactive X chromosome are a common feature of brca1 mutant and sporadic basal-like breast cancer

Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects